Expert consensus suggests considering pharmacotherapy when there is: Significant weight regain from nadir weight BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m Absence of anatomical complications requiring surgical revision Adequate adherence to nutritional and behavioral recommendations Patient willingness to engage in long-term pharmacotherapy The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines emphasize that pharmacologic therapy should complement, not replace, lifestyle interventions and ongoing bariatric surgical follow-up
Regardless of whether youre on a GLP-1 for diabetes, weight loss, cardiovascular disease, or something else, your prescription could potentially cost more than $1,000 per month
One of those medications, Wegovy, is also FDA-approved for the treatment of cardiovascular disease
Second, depending on your location, orders shipped internationally may be subject to import duties, customs fees, or additional processing time
It also slows digestion (stomach emptying), which helps control appetite